Subcutaneous IGF-1 is not beneficial in 2-year ALS trial  

Oleh:

Sorenson, E. J. ; Windbank, A. J. ; Mandrekar, J. N.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Neurology (Official Journal of The American Academy of Neurology) vol. 71 no. 22 (Nov. 2008), page 1770-1775.
Topik: PULMONARY EMBOLISMS; DEEP VENOUS THROMBOSES

Ketersediaan

Perpustakaan FK Nomor Panggil: N11.K.2008.05 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Background: Previous human clinical trials of insulin-like growth factor type I (IGF-1) in amyotrophic lateral sclerosis (ALS) have been inconsistent. This phase III, randomized, double-blind, placebo-controlled study was undertaken to address whether IGF-1 benefited patients with ALS. Methods: A total of 330 patients from 20 medical centers were randomized to receive 0.05 mg/kg body weight of human recombinant IGF-1 given subcutaneously twice daily or placebo for 2 years. The primary outcome measure was change in their manual muscle testing score. Secondary outcome measures included tracheostomy-free survival and rate of change in the revised ALS functional rating scale. Intention to treat analysis was used. Results: There was no difference between treatment groups in the primary or secondary outcome measures after the 2-year treatment period. Conclusions: Insulin-like growth factor type I does not provide benefit for patients with amyotrophic lateral sclerosis.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali